Simprevir (trade name Olysio) has been available since May 2014 for the treatment of adults with chronic hepatitis C infection. The Institute for Quality and Efficiency in Health Care (IQWiG), pursuant to the Pharmaceutical Market Restructuring Act (AMNOG), has checked whether this new drug compared with appropriate comparator therapy, as determined by the Joint Federal Committee (G-BA), offers an additional benefit.

The manufacturer's dossier provides evidence of an additional benefit of simeprevir in patients with hepatitis C virus (HCV) genotype 1 infection who were previously untreated or had relapsed after successful initial therapy. But the extent of added benefit cannot be classified.  In adults with HCV genotype 1 infection, in which previous treatment had no effect (non-responders), there is an indication of a considerable added value. For two additional patient populations, actionable data are missing, so an additional benefit has not been established.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/simeprevir-bei-hepatitis-c-zusatznutzen-bei-bestimmten-patienten.6265.html?&et_cid=4&et_lid=%25208 [German]